Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$8.74 USD
+0.13 (1.51%)
Updated Aug 16, 2024 02:09 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Precision BioSciences, Inc. [DTIL]
Reports for Purchase
Showing records 1 - 20 ( 57 total )
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
HBV Webinar Takeaways: Gene Editing Emerges as Promising Novel Therapy; PBGENE-HBV Phase 1 Data Expected 1H25; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; May 29 HBV Webinar to Spotlight Lead Gene Editing Program; Pipeline Progressing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Regains Control of Partnered Gene Editing DMD Program; Lead Programs Progressing to First-in-Human Trials; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Multiple ARCUS Gene Editing Programs Progress Toward Phase 1 in 2024; 4Q23 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Alignment Puts HBV Gene Editing Program on Track For IND in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
HBV Gene Editing Program on Track for IND in 2024; Azer- Cel Collaborations Push Cash Runway into 2H26; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Preclinical Data on Lead HBV Program Expected at AASLD; Early Stage Gene Editing Pipeline Progressing
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
HBV Conference Takeaways: Lead Gene Editing Program on Track for IND Filing in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Broad Pipeline Progress; Pivoting ARCUS Focus to In Vivo Gene Editing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Azer-Cel Transaction Worth $227M to Extend Cash Runway to 3Q25; Lowering Price Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; RD Day on September 12 to Detail Gene Editing Strategy and Pipeline Plans
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Advancing Discussions With Multiple Potential Partners; Hosting Gene Editing RD Day on September 12; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Allogeneic CAR T Update Demonstrates Improved Safety Profile of Azer-Cel, Promising Stealth Cell Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Promising Preclinical Data Emerges at ASGCT in Partnered DMD Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Bright Spotlights on CAR T Portfolio Update Expected Later in May, Gene Editing RD Day in Mid-2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Broad Pipeline Progressing; CAR T Portfolio Update Expected in April or May; R&D Day Planned for Mid-2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Analysis of Allogeneic CAR T Product Enabling Optimizations Across First- and Second-Generation Compounds; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Precision BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Lead Anti-CD19 Allo CART Programs on Track; Discontinues BCMA Program; Reducing Price Target to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P